id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2001-E-0149-0003,FDA,FDA-2001-E-0149,U.S. Patent and Trademark Office to Glaxo Wellcome Inc.,Rule,CEP-Certificate Extending Patent Term,2007-04-23T04:00:00Z,2007,4,,,2008-04-25T02:26:25Z,,0,0,09000064804ddce0
FDA-2001-E-0149-0002,FDA,FDA-2001-E-0149,HFD-005 to US Patent & Trademark Office,Other,LET-Letter,2003-07-28T04:00:00Z,2003,7,,,2008-04-25T02:26:25Z,,0,0,09000064804ddcdf
FDA-2001-E-0149-0001,FDA,FDA-2001-E-0149,FDA,Notice,N-Notice,2002-11-14T05:00:00Z,2002,11,2002-11-14T05:00:00Z,2003-01-14T04:59:59Z,2008-04-25T02:26:25Z,,0,0,09000064804ddcba